Form4insider filings, from the source

SEC Form 4 · accession 0001193805-16-003952

ALPINE IMMUNE SCIENCES, INC. · ALPN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
DEERFIELD MANAGEMENT CO
Director · 10% Owner
James E Flynn
Director · 10% Owner
Period of report
Sep 12, 2016
Accepted (ET)
Sep 14, 2016 · 4:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626199

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F1,F3,F4,F2$7.77Sep 12, 2016A12,300A—Sep 12, 2026Common Stock12,30012,300I

Explanation of responses

Remarks

Howard P Furst, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Editas Medicine, Inc. filed with the Securities and Exchange Commission on February 2, 2016 by Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.